---
schema_version: "secwatch.filing_event.v1"
accession: "0001665988-26-000041"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2026-08-05T11:40:11+00:00"
generated_at: "2026-08-05T11:45:24.853371+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q2 revenue $153.2M (+4%), GAAP EPS $0.47; initiates strategic alternatives review

## Summary
- Q2 revenue $153.2M (+4% YoY); GAAP EPS $0.47 vs $0.11; non-GAAP EPS $0.22 vs $0.21.
- Pain Treatments revenue $81.7M (+11.5%); Surgical Solutions $50.4M (-4.5%); Restorative Therapies $21.1M (-2.4%).
- Reaffirmed FY2026 guidance: net sales $600-610M, adjusted EPS $0.75-0.79, cash from ops $84-89M.
- Board formed independent committee to evaluate strategic alternatives including sale, after unsolicited proposal.
- Made $20M discretionary principal prepayment on term loan during Q2.

## SEC filing metadata
- accession: 0001665988-26-000041
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2026-08-05T11:40:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/0001665988-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/bvs-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001665988-26-000041
- JSON: https://secwatch.observer/filing/0001665988-26-000041.json
- Plain text: https://secwatch.observer/filing/0001665988-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.